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SUMMURY 
Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disease 
characterized by a specific chromosomal translocation t(9;22) that gives rise 
to a fusion gene BCR-ABL1. The oncogenic product BCR-ABL1 is a 
constitutively active tyrosine kinase that promotes cell proliferation and inhibits 
apoptosis of the leukemic clone. 
In the era of target therapy, the treatment of CML patients in chronic phase 
(CML-CP) with tyrosine kinase inhibitors (TKIs) showed a substantially life 
expectancy improving. However, a large number of them develop drug 
intolerance or resistance and relapse after TKIs treatment.  
If on one hand, BCR-ABL1 dependent Imatinib resistance can be overcome 
by second or third generation TKIs, on the other hand, the molecular 
mechanisms that underlie BCR-ABL1 independent resistance are not well 
clarified. It is becoming evident that persistent leukemic stem cells (LCSs) can 
lead to disease relapse at the time of TKI withdrawal in a relevant portion of 
the patients. 
In this context, we sought to evaluate Nanog role in the regulation of CML cells 
response to TKI therapy. Nanog is an essential transcription factor involved in 
the regulatory networks that are responsible for stemness in embryonic 
pluripotent stem cells. Furthermore, functional studies have provided 
evidences that the expression levels of Nanog play crucial role in malignant 
diseases promoting tumorigenicity, invasiveness, and therapeutic resistance. 
We have observed a significant level of Nanog protein expression in 
Philadelphia positive (Ph+) K562 cells after Imatinib treatment whether 
compared to untreated control since 24 hours of treatment, with a persistence 
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of expression at least until 72 hours. Moreover, we also have described a time-
dependent up-regulation of Nanog protein in K562 Ph+ cell line treated with 
increasing doses not only of Imatinib (first generation TKI), but also of Nilotinib 
(second generation TKI), confirming the correlation between TKI treatment and 
Nanog overexpression. Moreover, we demonstrated that the Nanog protein 
overexpression is restricted to alive cells and persists after TKI withdrawal. 
The RT-qPCR analysis revealed that Nanog expression is modulated at 
transcriptional level after exposure to first and second generation TKIs 
showing a correlation with Nanog protein increasing.  
Furthermore, we proved that Nanog overexpression is independent from BCR-
ABL1 activity; indeed, after Imatinib treatment, in K562 cell line, BCR-ABL1 
expression was reduced, instead Nanog expression was increased. Finally, 
we evaluated Nanog expression in two cohorts of CML-CP patients at baseline 
treated with 1) Imatinib or 2) Nilotinib and we observed a significant up-
regulation in Warning or Failure responder patients; contrariwise, Optimal 
responder patients showed a significant down-regulation of Nanog mRna 
expression. 
Taken together, these findings demonstrate the involvement of Nanog in TKI 
resistance in K562 Ph+ cell line and identify Nanog as a potential marker of 
molecular response in CML patients.  
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1.1 Chronic Myeloid Leukemia. 
1.1.1 Clinical presentation 
The Chronic Myeloid Leukemia (CML) is a clonal 
myeloproliferative disorder characterized by an accumulation of 
several types of myeloid precursor cells that retain the capacity to 
differentiate during Chronic Phase of the disease (CP-CML) [1]. 
CML was described for the first time 165 years ago and may be regarded as a 
paradigm of modern oncology. In 1960 Nowell and Hungerford described the 
hallmark of CML through the discovery of the Philadelphia (Ph) chromosome 
and its association with the development of CML. The Ph chromosome was a 
breakthrough in cancer biology. It is an abnormal short chromosome 22 (22der 
or 22q-) and was the first consistent chromosomal aberration associated with 
a specific type of leukemia. Indeed, it is the genetic hallmark in about 90% of 
CML patients at diagnosis. Ph chromosome is generated by the reciprocal 
translocation t(9;22)(q34;q11) of the Abelson (ABL1) proto-oncogene tyrosine-
protein kinase gene located on chromosome 9 to the breakpoint cluster region 
(BCR) gene located on chromosome 22. The results is a novel fusion gene 
BCR-ABL1 that encodes a tyrosine kinase with an abnormal activity, which 
deregulates cell proliferation, differentiation and apoptosis [2]. 
It has been proposed that CML may be the result of multistep pathogenic 
process. Initially, the acquisition of t(9;22) occurs in a single Hematopoietic 
Stem Cell (HSC) that gains a proliferative advantage and/or aberrant 
differentiation capacity over the normal cells [3].  
The Ph positive (Ph+) Leukemia stem cell (LSC) is capable of expansion in 
both the myeloid or lymphoid lineages. It may involves myeloid, monocytic, 
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erythroid, megakaryocytic, B-lymphoid and occasionally T-lymphocytic 
lineages, although expansion is predominantly in the granulocyte compartment 
of the myeloid lineages in the bone marrow. [4] 
The incidence of CML is approximately 1 per 100,000 population per year with 
a slight male preponderance and accounts for 20% of all leukemia affecting 
adults. The median age at onset is from 45 to 55 years and about 50% of cases 
are diagnosed by physical examination or blood tests. CML can be classified 
into three disease phases: chronic phase (CP), accelerated phase (AP), and 
blast phase (BP). CML patients diagnosed in the United States are 
asymptomatic in about 30 to 50% of cases and more than 90% are diagnosed 
at a CP [5]. CML-CP occurs a relatively indolent presentation in patients, with 
an increase of immature and mature myeloid elements and a retention of 
hematopoietic differentiation. The most common features at presentation are 
an high white blood cell counts, splenomegaly fatigue, weight loss, abdominal 
fullness, bleeding, purpura, anemia, and thrombocytosis [6]. At diagnosis of 
CML, about 10% of patients are Ph negative; in these cases, the Ph 
chromosome is absent at cytogenetic analysis, but the translocation can be 
detected by molecular analysis. Furthermore, about 5% of patients present 
variant translocations involving the chromosome 22 and a chromosome other 
than the chromosome 9 in the simple variant, whereas one or more 
chromosomes are involved in addition to chromosomes 9 and 22 in the 
complex variant. However, patients with Ph-variants have response to therapy 
and prognosis similar to Ph-positive CML[5]. 
The AP and BP phenotypes are much more different and aggressive than CP, 
and these two phases are characterized by a drastic reduction of cellular 
differentiation with the presence of myeloid or lymphoid blast cells in peripheral 
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blood. Most patients evolve into AP prior to BP, but the 20% evolve into BP 
without AP warning signals. AP might be insidious or presenting worsening 
anemia, splenomegaly and organ infiltration. BP presents as an acute 
leukemia with worsening constitutional symptoms, bleeding, fever, and 
infections [2, 5]. The progress to acute leukemia is associated with secondary 
cytogenetic changes like additional chromosomal abnormalities include 
trisomy 8, isochromosome 17, trisomy 19, duplication of the Ph chromosome 
[7] with high levels of BCR-ABL1 expression, microsatellite instability and loss 
of heterozygosity [8]. Moreover, the BC induction could be promoted by 
mutations in p53, a tumor suppressor gene with negative regulatory function 
in cell cycle progression [9]. 
1.1.2 Diagnosis 
The diagnosis of typical CML consists in the identification of Ph chromosome 
abnormality, the t(9;22)(q34;q11) by cytogenetic analysis or fluorescent in situ 
hybridization (FISH). In FISH analysis the fluorescent probes to BCR and 
ABL1 genes hybridize a specific genomic sequence. Thus, the BCR-ABL1 
fusion gene is observed by a co-localization signal. Reverse transcriptase-
polymerase chain reaction (RT-PCR) amplifies the region around the splice 
junction between BCR and ABL1. Qualitative PCR assay is useful for CML 
diagnosis giving information about the presence of BCR-ABL1 transcript. The 
above-mentioned method has been optimized for the detection of all typical 
BCR-ABL1 transcripts e1a2, b2a2, b3a2 and some atypical transcripts such 
as fusions to ABL1 exon 3. Whereas, quantitative RT-PCR is highly sensitive 
for the detection of minimal residual disease (MRD) providing information 
about the amount of BCR-ABL message [5]. 
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1.2 The molecular biology of CML 
It is widely accepted that the acquisition of the t(9;22) BCR-ABL1 traslocation 
is the initial event of the CML-CP. At first, this acquisition occurs in a single 
HSC that gains proliferative advantage ad/or aberrant differentiation capacity 
over normal cells, giving rise to an expansion of the myeloid compartment [2] 
[1]. 
1.2.1 ABL1 gene 
The ABL1 gene encodes a member of the family of a non-receptor tyrosine 
kinase protein and it is the human homologue of the v-abl oncogene carried 
by the Abelson murine leukemia virus (A-MuLV). It is located on chromosome 
9 and encodes a 145 kDa protein with a molecular structure of 12 exons and 
several introns. The alternative splicing of the first exons, exon 1a e 1b, gives 
rise two mRNA isoforms, a 6-kb and a 7-kb molecules, coding 1122 and 1142 
amino acids respectively [10]. ABL1 kinase activity is regulated by a myristol 
group that is localized on N-terminal domain, where there are also three SCR 
homology domains (SH1, SH2 and SH3).The catalytic domain SH1 consists of 
the C-lobe and the N-lobe, with an activation loop that is tyrosine 
phosphorylated at 393 (Y393) when the kinase is activated. The ABL1 auto-
inhibition is attributed to SH2 and SH3 domains. A proline-rich sequence is 
located at the center of the protein and interacts with SH3 domain of other 
protein. 
The SH2 domain position on the N-lobe mediates allosteric activation of the 
kinase domain that is independent of its phosphotyrosine binding capability. 
The SH2-KD is most important in the oncogenic fusion BCR-ABL1, indeed it 
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was shown to be essential for leukemogenicity and represents an allosteric 
target for pharmacological intervention [11].  
The C-terminal non catalytic portion is constituted by a nuclear localization 
sequence, a nuclear export sequence, a DNA binding site [12], a p53 binding 
site [13] and an actin binding region [14]. Several functions have been 
attributed to ABL1 protein, such as the regulation of the cell cycle in the cellular 
response to genotoxic stress and the transmission of information about the 
cellular environment through integrin signaling.[15] 
 
1.2.2.1 BCR gene 
The Breakpoint cluster region (BCR) gene is composed of 25 exons, including 
two alternative first (e1’) and second (e2’) exons. The normal BCR gene codes 
for two major proteins of 160 kDa and 130 kDa size, these proteins are derived 
from the 7.0- and 4.5-kb BCR transcripts, respectively. 
The BCR gene is now known to be a complex molecule with many different 
functional domains. The N-terminal consists of the serine-threonine kinase 
domain, the SH2-binding domain characterized by three to five amino acids 
including a phosphotyrosine, and an oligomerization domain that is 
characterized by a heptad repeat of hydrophobic residues between amino 
acids 28 and 68. The central sequences have GEF homology (activate G 
proteins by exchanging), that catalyze the exchange of guanidine triphosphate 
(GTP) for guanidine diphosphate (GDP). At C-terminal there is a GAP domain 
homology (inactive G proteins) with activity for a Ras-related GTP-binding 
protein (p21Rac) that regulates actin polymerization and NADPH oxidase 
activity in phagocytic cells [16]. Moreover, BCR can be phosphorylated on 
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several tyrosine residues, especially tyrosine 177, which binds Grb-2, an 
important adapter molecule involved in the activation of the Ras pathway[15]. 
 
1.2.3 BCR/ABL1 fusion gene. 
The reciprocal translocation between chromosomes 9 and 22 leads to the 
BCR/ABL1 fusion protein formation that occurs in 95% of CML cases. The 
same cytogenetic translocation also occurs in about 20% of adult Acute 
Lymphoblastic Leukemia (ALL), 5% of pediatric ALL and rare cases of Acute 
Myeloid Leukemia (AML). 
In most CML patients and in one third of patients with Ph-positive ALL, the 
BCR breakpoints are localized within a 5.8-kb area defined as the Major 
Breakpoint Cluster Region (M-bcr). M-bcr consists of five exons termed M-bcr 
exons b1–b5. These exons are located within the central region of the BCR 
gene and are equivalent to exons 11–15 (e11–e15) of this gene. Most breaks 
occur immediately downstream of exon 2 or of the M-bcr and the alternative 
splicing, can produce fusion transcripts with b2a2 or b3a2 junctions. These 
mRNA molecules lead to a chimeric protein of 210 kDa (P210 BCR/ABL1).  
In the case of Ph+ ALL the breakpoints are further upstream, in the 54.4-kb 
region between the alternative BCR exons e29 and e2, termed minor 
breakpoint cluster region (m-bcr). ALL is characterized clinically by 
pronounced monocytosis and the fusion transcript produces an oncoprotein of 
190 kDa (p190 BCR/ABL). A third fusion gene (e19a2) encoding a 230 kDa 
(p230 BCR/ABL) protein, was associated with the rare chronic neutrophilic 
leukemia (CMML). Each of these onco-proteins contains the same segment of 
ABL, but differs for BCR segment. Sporadic cases with other junctions, such 
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as b2a3, b3a3, e1a3, e6a2, or e2a2,42 have been reported in patients with 
ALL and CML.[16] 
In contrast to BCR, the breakpoints within the ABL1 gene at 9q34 can occur 
anywhere over a large area (greater than 300 kb), either upstream of the first 
alternative exon Ib, or downstream of the second alternative exon Ia, or 
between the two. Independently from the exact breakpoint location, splicing of 
the primary hybrid transcript yields an mRNA in which BCR sequences are 
fused to ABL exon a2 [15]. 
The native c-ABL tyrosine kinase is located partially in the nucleus and its 
kinase activity is tightly regulated. The BCR–ABL fusion results in the 
production of a constitutively active cytoplasmic tyrosine kinase that does not 
block differentiation, but enhances proliferation and viability of myeloid lineage 
cells. BCR–ABL is likely sufficient to cause CML, but over time other genetic 
events occur and the disease progresses to an acute leukemia [17]. 
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Figure 1. (A) The t (9;22) reciprocal translocation results in the creation of 
the BCR-ABL1 fusion gene which is transcribed to a BCR-ABL1 mRNA (B) 
and translated to a BCR-ABL protein (C). In panel D, is showed the protein 
interaction with Imatinib in ATP binding loop. [18] 
  
A 
B 
C 
D 
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1.2.4 BCR/ABL1 kinase signaling pathways 
In physiological conditions, ABL protein transduces signals from cell-surface 
growth factors and adhesion receptors to regulate cell differentiation, cell 
division, cell adhesion, proteasome degradation and stress response 
processes. It shuttles between the nucleus and cytoplasm of cells. However, 
when it is fused to BCR, ABL protein loses this property and is mainly retained 
within the cytoplasm where it interacts with the majority of proteins involved in 
the oncogenic signaling pathways.  
The BCR/ABL leukemogenesis potential is regulated by the sequences within 
the first exon of BCR. The link of phosphorylated tyrosine (Y177) in BCR SH2 
domain with GRB-2 protein activates the Ras signaling pathway that is most 
important in BCR/ABL mediated transformation. GRB-2 not only functions in 
normal development and mutagenesis but also plays a role in oncogenesis. 
When Y177 in the BCR SH2 domain is mutated, it gives rise an abolishment 
of GRB-2 binding with BCR-ABL1 and consequently the Ras activation was 
reduced.[19] 
Son of Sevenless (SOS) is constitutively associated with the GRB2 SH3 
domain, thereby with BCR/ABL-GRB2 it forms the GRB2/GAB2/SOS complex 
that stimulates constitutive activation of the RAS downstream pathway. The 
evolved pathways are Ras–mitogen-activated protein kinase (MAPK) leading 
to increased proliferation, the Janus-activated kinase (JAK)–STAT pathway 
leading to impaired transcriptional activity, and the phosphoinositide 3-kinase 
(PI3K)/AKT pathway resulting in increased apoptosis. The activation of 
Mitogen-activated protein (MAP) extracellular signal-regulated kinase 
(ERK)1/2 (MEK) lead to a G1 to S phase transition ensuing an abnormal cell 
proliferation[20]. The GRB2/GAB2/SOS complex triggers the PI3K/AKT 
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pathway, which promotes and enhances cell proliferation by inducing p27 
proteosomal degradation and by mTOR upregulation blocking important 
cellular processes such as autophagy. 
BCR-ABL1 interacts with many cytoplasmic proteins, which function as 
adaptor molecules, creating multi-protein signaling complexes. BCR/ABL1 
activates the serine-threonine kinase AKT through PI3K, which phosphorylates 
downstream substrates like Bad, Caspase 9, Mdm2, and Ask1 that regulate 
the apoptotic machinery. Furthermore, the Akt-mTOR pathway stimulates the 
HIF-1α activation mimicking hypoxic conditions, and promotes the glucose 
transporter GLUT1 expression, which is responsible of glucose-dependent 
ROS production [21, 22]. 
All these events lead a prolonged survival and expansion of the abnormal 
clone. Moreover, STAT1 and STAT5 (signal transducer and activation of 
transcription) play a key role in BCR-ABL1 signaling. Indeed, they are 
constantly active in Ph+ positive cell lines and in primary cells of CML patients. 
STAT1 and STAT5 act in a JAK-independent manner through a direct 
association of their SH2 domains with phosphorylated tyrosine on BCR-ABL1 
[23, 24].  
The STAT5 phosphorylation gives rise the up-regulation of the anti-apoptotic 
molecule BCL-xL together with the inactivation of the pro-apoptotic molecule 
BAD by AKT [25]. Another target of the BCR/ABL activity is the proto-oncogene 
MYC that is expressed at a high level in CML cells. In particular, it is 
overexpressed in blast phase compared to the chronic phase, independently 
of RAS pathway. Indeed, Myc seems to be up-regulated directly by the ABL 
SH2 region [26]. All reported activated signaling pathways converge into a 
unique terminal point: loss of control of proliferation and expansion of the 
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leukemic clone. Defining the relative contribution of each signal transduction 
pathway to the leukemic process is an important area of research because the 
combination of a tyrosine kinase inhibitor (TKI) with a downstream inhibitor 
may be clinical successful strategy. 
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Figure 2. Schematic representation of the molecular pathway activated by 
BCR-ABL1. BCR-ABL1 phosphorylation of BCR Tyr177 is essential for BCR-
ABL1–mediated leukemogenesis. The BCR-ABL/GRB2 complex recruits 
SOS, which is constitutively associated with the GRB2 SH3 domain. The BCR-
ABL/GRB2/SOS complex stimulates conversion of the inactive GDP-bound 
form of Ras to its active GTP-bound state, and activation of the scaffold 
adapter GAB2. As a consequence, the GRB2/GAB2/SOS complex causes 
constitutive activation of the RAS downstream pathway, thereby activating 
MEK1/2 and MAPK proteins and resulting in abnormal cell proliferation.[27]  
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1.3 Therapy and monitoring 
1.3.1 The conventional chemotherapeutic treatment. 
Before the BCR/ABL1 discovery and the introduction of Tirosin Kinase Inhibitor 
(TKI), CML was managed with conventional chemotherapies. 
Busulfan and Hydroxyurea (HU) was given in low doses and rarely produced 
cytogenetic remissions and an improving overall survival. In a clinical trial was 
possible to induce cytogenetic remissions in CML-CP patients with intensive 
chemotherapy and splenectomy in a significant fraction of patients. However, 
the patients overall survival was modest and the blastic crisis transformation 
was observed within 5-6 years [28]. On the other hand, patients treated with 
Interferon alpha (INF-alpha) showed a survival increase compared to those 
that received HU and Busulfan. In particular, INF-alpha induced a persistence 
of complete remission still after stopping treatment. However, INF-alpha 
showed a high toxicity that is not tolerate by most patients. In addition, using 
both PCR and FISH analysis, small quantity of Ph+ cells could be detected in 
the majority of Bone Marrow (BM) patients with long-term cytogenetic 
remissions [29]. The curative therapy in majority of CML patients remained 
allogeneic bone marrow CD34+ hematopoietic stem cells transplantation 
(HSCT). Nevertheless, allogeneic HSCT is still a controversial treatment due 
to of the early mortality and the relatively high incidence of complications, 
including graft-versus-host-disease (GVHD), especially in older patients who 
are less able to tolerate the intensive treatment.[30] 
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1.3.2 The Target Therapy 
1.3.2.1 Imatinib (Gleevec) 
Imatinib mesylate, an example of rational drug design, was the first Tyrosine 
Kinase Inhibitor (TKI) used in a clinical setting with excellent results. It is a 2-
phenylaminopyrimidine that acts as a specific inhibitor of several tyrosine 
kinase enzymes. STI571 or Imatinib was identified in the late 1990, when 
Druker and colleagues demonstrated the high selectivity to ABL1 kinase in cell 
BCR/ABL positive [31]. Imatinib is an ATP competitive inhibitor; that binds 
ABL1 inactive conformation of BCR-ABL1 kinase and blocks the ATP binding 
site. In this way, Imatinib avoids the transfer of a phosphate group to tyrosine 
on the protein substrate and subsequent conformational switch to the active 
form [32]. As the result, this drug inhibits proliferation and induces apoptosis 
in BCR-ABL1 positive cell lines as well as fresh in Ph+ leukemic cells of CML 
patients. Imatinib also inhibits the receptor tyrosine kinases for platelet derived 
growth factor receptor (PDGF) and stem cell factor (SCF) called c-kit and ARG 
but not the Src family kinases. [31, 33] 
In phase I and II clinical trials, Imatinib showed a great efficacy with more than 
90% complete hematological response (CHR) and 30-40% complete 
cytogenetic responses (CCyr) of enrolled CML patients. 
In phase III, newly diagnosed patients with CML-CP were enrolled in an 
International Randomized Study of Interferon and STI571 (IRIS) in which 
Imatinib at single daily dose (400 mg) and IFN-alpha and cytarabine was 
compared.  
The IRIS highlights an Imatinib superiority in rate of CHR, MCyR and CCyR 
respect to IFN alpha plus cytarabine. Moreover, was demonstrated that 
Imatinib treatment significantly reduced the disease progression to AP or BC. 
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Therefore, Food and Drug Administration (FDA) approved Imatinib as first-
choice treatment for newly diagnosed CML in December 2002 [33]. 
Unfortunately, after one decade of clinical trial applying Imatinib as front line 
therapy for patients with CML, it is well known that TKI is not able to eradicate 
leukemia and primary or secondary drug resistance eventually occurring in the 
first two years of treatment. Hence, new drugs with ever-increasing specificity 
and anti-leukemia power have been developed.  
 
1.3.2.2 Second generation TKIs 
The identiﬁcation of Imatinib resistance led to a focused effort to develop 
additional TKIs with more efficacy against kinase speciﬁc mutations. 
Dasatinib (BMS-354825, Sprycel) is a second-generation BCR-ABL1 TKI 
indicated for Imatinib resistant or intolerant CML patients. It is an ATP-
competitive inhibitor non-phenylaminopyrimidine-based drug and inhibits 
BCR-ABL1 tyrosine kinase both in the active and in inactive conformation of 
ABL1 ATP-binding domain [34]. Dasatinib is a dual Src-Abl inhibitor. In 
particular, inhibits Src-family kinases, ABL1 and other tyrosine kinases like 
PDGFR and c-Kit. It is more potent inhibitor in comparison with Imatinib 
mesylate and shows activity against most of the well-characterized BCR-ABL1 
mutants except T315I [35].  
Nilotinib (AMN-107, Tasigna) as well as Dasatinib is a second generation TKI 
and it was developed from Imatinib by crystallographic analysis. It is an ATP-
competitive phenylaminopyrimidine that, similar to Imatinib, binds the same 
inactive conformation of ABL1 kinase. Nilotinib blocks the substrate binding 
site proximal to the activation loop and causes the inhibition of the ATPase 
catalytic activity by the disruption of the ATP–phosphate binding site [36]. 
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Nilotinib has a higher affinity for ABL1 kinase domain than Imatinib, resulting 
in a greater potency and selectivity, whereby CyR and MR are significantly 
faster. In addition, it inhibits the activity of Arg, Kit, and PDGFR, but not Src 
family kinases [37]. Nilotinib is indicated for the treatment of CML patients with 
Imatinib resistance or intolerance, is effective against 32 out of 33 Imatinib-
resistant point mutations, except T315I mutation [35]. Nevertheless, patients 
continually encountered with some hematological and non-hematological 
toxicity during the course of study. [18] ENESTnd and DASSION studies 
assessed the efficacy of Nilotinib (400 mg twice daily) and Dasatinib (140 mg 
once daily) versus 400mg of Imatinib in newly diagnosed CML-CP patients. 
The studies highlighted that Dasatinib and Nilotinib are superior in terms of 
achieving faster CCyR, MMR and lower progression rates than 400mg of 
Imatinib. They are well-tolerated therapeutic option for patients with CML-CP 
resistant or intolerant to Imatinib therapy [38, 39]. 
Finally, Bosutinib SKI-606 is an alternative second generation TKI; originally, 
it has been proposed as a Src tyrosine kinase inhibitor, but was subsequently 
found as ABL1 tyrosine kinase inhibitor.  
 
1.3.2.3 Third generation TKI 
Ponatinib is a third generation TKI active against unmutated and mutated 
BCR-ABL1. It has efficacy for the threonine-to-isoleucine mutation at position 
315 (T315I), which is present in up to 20% of patients with TKI resistance. A 
complete cytogenetic response and clinically significant activity was observed 
in CML and Ph+ ALL patients including those with T315I mutation [40]. 
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1.4 Molecular monitoring in CML  
As results of the TKI success, it was necessary to introduce guidelines to 
monitor the treatment response in CML patients. The monitoring of the 
response to TKIs therapy allows to detect early relapse of disease, thus a good 
management strategies in CML patients 
There are three different types of therapy response: hematologic response 
(HR), cytogenetic response (CyR), and molecular response (MR) [41]. 
Complete hematological response (CHR) consists in a normalization of 
peripheral blood counts without immature blood cells and normal spleen size. 
The CyR is quantified by determining of the number of Ph+ metaphase cells. 
Using chromosome banding analysis (CBA) on BM cells and counting at least 
20 metaphases may be observe: 1) the CCyR in the absence of Ph+ 
metaphase cells; 2) the major cytogenetic response (MCyR) when are present 
0-35% Ph+ metaphase cells; 3) the partial cytogenetic response when the Ph+ 
cells are 1% to 34%. 
The European Leukemia Net (ELN) recommendations suggest cytogenetic 
testing at 3 and 6 months, then every 6 months until a CCyR is achieved and 
subsequently every 12 months whether regular molecular monitoring cannot 
be assured. CBA, used to assess the degree of CyR, can be substituted by 
FISH of blood interphase cell nuclei only for the assessment of CCyR, which 
is then defined by <1% BCR-ABL1 positive nuclei of at least 200 nuclei. 
The MR is determined by a decrease of the amount of BCR-ABL1 mRNA in 
the peripheral blood by quantitative real time polymerase chain reaction (qRT-
PCR). Modern qRT-PCR can be detect residual disease to a sensitivity of 
0,01% and often to 0.001. MR is assessed, according to the International Scale 
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(IS), as the ratio of BCR-ABL1 to control transcript (usually ABL1 and GUS 
beta). It is expressed and reported as percent of BCR-ABL1 on a log scale, 
where 10%, 1%, 0.1%, 0.01%, 0.0032%, 0.001% correspond to a decrease in 
tumor load of 1, 2, 3, 4, 4.5, and 5 logs respectively, below the standard 
baseline that was used in IRIS study [18, 42]. 
Since the inter-laboratory results cannot be compared, a methodological 
standardizing was necessary between laboratories. After many 
considerations, several genes are widely accepted as suitable controls, 
including ABL1, GUS, and BCR. The expression of the control genes is 
critically important because describes the sensitivity of the BCRABL1 detection 
assay. At this time, it is recommended that a sample should have at least 
10,000 ABL1 or 24,000 GUS copies to pass minimum quality standards [42]. 
In 2006 a group of CML experts by means of the European Leukemia Net 
began a project with the aim to develop recommendations for disease 
management. In this regard, both cytogenetic and RT-qPCR dates was include 
for disease monitoring. 
In the recommendation of 2009 Baccarani and colleagues, formally defined 
the management of CML patients treated with Imatinib in front-line. In 2013 an 
in the latest 2015, after the introduction of second and third generation TKI, 
CML therapy guidelines was revised. 
Regardless of the TKI is used an optimal (OR), suboptimal (WR) or failure (FR) 
response. The optimal response is defined when BCR-ABL1 transcript levels 
is <10% at 3 months, <1% at 6 months and <0.1% from 12 months. The OR is 
associated with the best long-term outcome, with a duration of life comparable 
with that of the general population, indicating that there is not suggestion for a 
change in the treatment. A BCR-ABL1 transcript levels >10% at 6 months and 
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>1% from 12 months define failure response. The failure indicates that the 
patient should receive a different treatment to limit the risk of progression and 
death. Between OR and FR there is an intermediate warning zone that requires 
more frequent monitoring, known as suboptimal. BCR-ABL1 transcript levels 
is >1-10% at 6 months and >0.1-1 % at 12 months. Suboptimal responders 
may be eligible for alternative approaches, although the condition of 
suboptimal response may be only transitory [43, 44]. 
The proportion of blasts in the blood and bone marrow together with age and 
spleen size are used in scoring system for the prediction of survival. The Sokal 
score was developed for patients treated with Busulfan while the Hasford score 
for patients treated with INF-α and either continue to have value in the TKI era. 
Recently, European Treatment and Outcome Study for CML (EUTOS) 
developed a new formula to predict prognosis, known as the EUTOS score. It 
is most simple and asses the progression free survival (PFS) and overall 
survival (OS). In particular, patients with low EUTOS score had significantly 
better 5-year PFS than patients with high EUTOS score. EUTOS, Sokal or 
Hasford scores are used with MR to describe the response achieved after a 
definite duration of TKI therapy [18, 45, 46]. 
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Definition of the response to TKIs (any TKI) as first-line treatment 
 
 Optimal Warning  Failure 
Baseline NA 
High risk 
or 
CCA/Ph+, 
major route 
 
NA 
3 mo 
BCR-ABL1 
≤10% 
and/or 
Ph+ ≤35% 
BCR-ABL1 
>10% 
and/or 
Ph+ 36-95% 
 
Non-CHR 
and/or 
Ph+ >95% 
6 mo 
BCR-ABL1 <1% 
and/or 
Ph+ 0 
BCR-ABL1 
1-10% 
and/or 
Ph+ 1-35% 
 
BCR-ABL1 >10% 
and/or 
Ph+ >35% 
12 mo 
BCR-ABL1 
≤0.1% 
BCR-ABL1 
>0.1-1% 
 BCR-ABL1 >1% 
and/or Ph+ >0 
Then, 
and at any 
time 
BCR-ABL1 
≤0.1% 
CCA/Ph– 
(–7, or 7q–) 
 Loss of CHR 
 Loss of CCyR 
 Confirmed loss of 
MMR* 
 Mutations 
 CCA/Ph+ 
 
Figure 3 .The definitions of response are the same for patients in CP, AP, and 
BP and apply to second-line treatment, when first-line treatment was changed 
for intolerance. The response can be assessed with either a molecular or a 
cytogenetic test, but both are recommended whenever possible. 
After 12 months, if an MMR is achieved, the response can be assessed by RT-
PCR every 3 to 6 months, and cytogenetic is required only in case of failure or 
if standardized molecular testing is not available. [42]   
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1.5 Mechanism of TKI resistance 
Despite the majority of CML-CP patients obtained an optimal clinical response, 
a large number of them develop drug intolerance or resistance and relapse 
after TKIs treatment. Several studies are focusing on the mechanisms of 
resistance by which the leukemic cells survived to TKIs treatment. It is widely 
shown that ABL kinase domain mutations are implicated in the pathogenesis 
of TKI resistance. Moreover, is evident that the presence of mutations does 
not clarify all cases of resistance in CML patients. Thus, BCR-ABL1 
independent mechanism may contributes to resistance to TKIs.  
1.5.1 BCR-ABL1 dependent resistance 
The mechanism of TKI resistance can be divided in primary or secondary. 
Primary or intrinsic resistance occurs when in a defined time point has not been 
achieved a drug response. On the other hand, secondary or acquired 
resistance is defined as loss of an established response to TKI treatment. In 
addition, secondary resistance is characterized by the loss of complete 
hematologic remission, of a complete cytogenetic response and of MMR and 
the detection of kinase mutations and clonal evolution.  
The criteria to define the failure response of first-line TKI therapy in CML 
patients has been summarized in ELN [44, 47]. 
Soon after the Imatinib introduction, several in vitro studies described some 
derived Ph+ cell line that developed resistance to TKI. BCR-ABL1 genomic 
amplification and above all BCR-ABL1 KD mutations are the best-
characterized mechanisms conferring resistance to TKI therapy [48]. 
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Firstly, le Coutre and Weisberg observed that the Imatinib resistance was the 
result of elevated ABL1 kinase activity due to a genetic amplification of the 
BCR-ABL1 sequence [49, 50].  
However, all of these samples were derived in vitro, thus could not described 
exhaustively the clinical TKI resistance. Until, Gorre et al identified by means 
FISH analysis genetic duplication of the BCR-ABL1 gene in cells of Imatinib-
resistant patients [51]. Actually, about 40-90% of Imatinib resistant patients 
carry a mutation in BCR-ABL1 that influence the oncogenic kinase 
properties[47]. The mutation frequency in patients with Imatinib resistance 
changed in the different phases of CML: from 25% to 30% in early CP patients 
on first-line Imatinib to approximately 70% to 80% of BC patients [52]. 
Mutations are located in several structural subunits of KD and can be divided 
into several groups: 1) mutations in the binding site of TKI; 2) mutations in the 
ATP binding site; 3) mutations in activate loop and 4) mutations that involve 
the catalytic domain. However, not all mutations give rise to Imatinib clinical 
resistance. Mutation analysis with Sanger sequencing, is usually performed in 
non-responder patients after TKI therapy and the results obtained may guide 
to the selection of subsequent TKIs.  
In the same BCR-ABL1 mRNA molecule can be find two or more codon 
changes know as compound mutations that characterized a single leukemic 
clone. Whereas polyclonal mutations are defined as two or more codon 
changes across different BCR-ABL1 mRNA molecules, and therefore 
presumably belonging to different mutant clones [53]. 
T315I represents a particularly critical mutation since it is rather frequent 
(about 15-20%) and induces not only Imatinib resistance, but also resistance 
to second-generation TKI, Dasatinib and Nilotinib. The Threonine with 
26 
 
Isoleucine substitution is located in ATP-binding site of ABL kinase. This 
mutation leads to a missing of binding site and a consequent structural 
hindrance that blocks the access for Imatinib, Nilotinib, Dasatinib and Bosutinib 
[47].  
Moreover, few mutations are known to confer clinical resistance to Nilotinib 
(Y253H, E255K/V, and F359V/C/I) or Dasatinib (V299L, T315A, and 
F317L/I/V/C) [54].  
The introduction of newer technologies with greater sensitivity allowed the 
identification of low-level mutations, but their specificity are limited for definite 
spectrum of mutations [55]. These mutations are below the detection limit of 
conventional direct sequencing and their clinical significance in CML patients 
has long been debated and remains unclear. However, retrospective studies 
have suggested that mutations found in rare Ph+ cells may fail to expand and 
their detection does not consistently predict relapse [56].  
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Figure 4. Map of mutations in the BCR-ABL1 KD identified in clinical samples 
from patients resistant to Imatinib. Key structural motifs within the KD are 
indicated: P-loop indicates phosphate binding loop, SH2 contact and SH3 
contact represent the contact regions with SH2 and SH3 domain-containing 
proteins, and A-loop indicates the activation loop. K247R and Y320C are in 
italics because they have been reported to be single-nucleotide 
polymorphisms. Numbering of residues is according to ABL1a isoform.[52] 
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1.5.2 BCR-ABL1 independent resistance 
In mutation-negative patients with CML, other resistance mechanisms 
have been investigated. Often, it is possible that more than one factor may 
cooperate to determine the resistance phenotype [52]. It is widely known that 
both in CML and in other malignancies the compensatory activation of 
intracellular signaling pathways may contribute to survival of Ph+ cells. 
Regarding cell-extrinsic factors, several studies have shown the importance of 
BM microenvironment for LCSs survival, and thus for TKI resistance. The BM 
microenvironment consists of a heterogeneous population of cells that provide 
the structural and physiological support for hematopoietic cells. It contains BM 
stromal cells (such as extracellular matrix and mesenchymal-derived cells) and 
promotes self-renewal, quiescence, differentiation, survival, proliferation of 
hematopoietic cells. These cells are supported by fibroblast-like bone marrow 
stromal cells, osteoblasts, and osteoclasts which secrete soluble factors and 
extracellular matrix proteins that mediate these functions [57]. This rich 
environment provides as a safe haven not only for normal and malignant 
hematopoietic cells, but also for epithelial tumor cells that metastasize to bone, 
offering protection from chemotherapeutic agents by common mechanisms. 
Environment-mediated drug resistance includes a combination of soluble 
factor mediated drug resistance and cell adhesion mediated drug resistance. 
Growth factors such as vascular endothelial growth factor (VEGF), 
transforming growth factor beta (TGFβ) and tumor necrosis factor alpha 
(TNFα) are required for the establishment of the metastatic microenvironment 
[58]. While BCR-ABL1 induces VEGF expression through a PI3K-mTOR 
dependent pathway [21], IL-6 supported myeloid differentiation in CML [59]. 
29 
 
Signals derived from the BM stroma can effectively reconstitute the 
downstream signaling pathway of BCR-ABL1 protein, such that CML cells can 
achieve BCR-ABL1 independent growth in the BM, making them resistant to 
BCR-ABL1 TKI. Several studies have been investigated BM niche role in the 
modulation of TKI effects on CML cells, confirming stroma-mediated drug 
resistance mechanisms. Moreover, a growing number of evidence have 
demonstrated that numerous intracellular pathways are responsible of BCR-
ABL1 independent resistance in CML cells. However, the nature of intrinsic 
resistance still needs to be clarified. 
It is widely accepted that pharmacological mechanisms are involved in drug 
resistance bringing on a significant variability of Imatinib plasma level among, 
in CML patients treated with standard daily dose of 400 mg [60]. The increase 
of Imatinib plasma levels is due to the serum protein α1-acid glycoprotein 
(AGP) that is able to bind  Imatinib in the plasma causing its intracellular 
concentration reduction [17]. The expression levels of MDR-1 gene is 
implicated in the resistance to various chemotherapeutic drugs. Both breast 
cancer resistance protein ABCG2 (BCRP) and ABCB1, a multidrug efflux 
pump, are correlated to the BCR-ABL1 resistance. Indeed, they regulate the 
intracellular uptake of Imatinib and are functionally overexpressed in CML 
stem cells of CML-BC patients, giving rise Imatinib resistance [61, 62]. A novel 
mechanism of acquired pharmacokinetic drug resistance in cancer patients 
that are chronically treated with Imatinib, involves a multidrug influx pump: the 
organic cation transporter 1 (OCT1). It mediates the active transport of Imatinib 
into the cells causing a decrease of the intracellular TKI. CML patients who 
have a suboptimal response to Imatinib have low OCT-1 activity, thus may 
predict for a less favorable molecular response. [63, 64] 
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Constitutive activation of Src kinases family is an example of BCR-ABL1 
independent signaling. SFKs have been demonstrated to regulate cell 
proliferation and survival and they have also been implicated in the 
development of late-stage CML [65]. 
Last but not least, our group described a novel BCR-ABL1–independent 
mechanism of resistance to IMA therapy in patients with CP-CML. In the study 
was suggested the phosphatase SHP-1 role in CML transformation and 
progression. SHP1 seems to be physically associated with BCR-ABL1 [66] 
being able both to block BCR-ABL1–dependent transformation and to mediate 
PP2A-induced BCR-ABL1 proteasome degradation. It is expressed at a low 
level in an Imatinib resistant CML cell line and in CML-CP patients that did not 
achieve MMR at 18 months. SHP-1 interacting with SHP-2 regulates the 
activation status of this latter phosphatase in CML cells, thus Imatinib resistant 
cell line with a low SHP- 1 expression shows a sustained activated status of 
SHP-2 after Imatinib treatment [67]. TKIs failed to kill BCR-ABL1-expressing 
CML stem cells because these cells are not addicted to BCR-ABL1 
oncoprotein for their survival. Quiescent CML stem cells account for 
approximately 0.5% of the CD34+ population and are characterized by the 
aberrant activation of pro-survival and self-renewal pathways regulated by cell-
intrinsic and cell-extrinsic factors. It has been shown that BCR-ABL1 is 
overexpressed in primitive CML cells. Despite Imatinib resistant stem cells 
CD34+CD38– carried a single copy of BCR-ABL1, they expressed significantly 
higher BCR-ABL1 transcript. Moreover, in the CML precursor cells there is  the 
upregulation of CXCR4 (cell surface adhesion molecule), an important 
molecule for stromal interaction regulating cell homing to the BM 
microenvironment [68]. 
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In light of the fact that a small subpopulation of quiescent CML cells exhibit an 
intrinsic resistance, the deep eradication of Ph+ cells may be precluded and 
then, the final cure of the disease too.[69] 
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Figure 5. Schematic representation of BCR-ABL1-dependent and -
independent mechanisms of TKI resistance: (1) Ampliﬁcation leads to the 
overexpression of the BCR-ABL1 kinase. (2) mutations in BCR-ABL1 lead to 
a conformation change in ABL and the ineffective binding of the TKI. (3) 
activation of other compensatory pathways (e.g. LYN). (4) overexpression of 
efﬂux transporters leads to low TKI levels in the cell. (5) downregulation of 
inﬂux transporter inhibits effective TKI shuttling in the cell. 
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1.5.3 The contribution of Leukemic stem cells (LSCs) in drug resistance  
In the contest of the BCR-ABL1 independent mechanisms, many 
studies are needed to understand the upstream mechanisms that make 
Leukemic stem cells insensitive to TKIs therapy. Consolidated evidence from 
stem cell biology have been provided the relationship between stem cells and 
tumor cells formalizing the notion that some tumors are composed of Cancer 
stem cells (CSCs): a cells subset with both self-renewal proprieties and 
propagation potentials that sustain tumor growth and remain in patients after 
convention cancer therapy. 
Most studies have highlighted that many pathways classically associated with 
normal stem cell development also regulate cancer progression. While, for 
most cancers, the target cell of the transformation events is unknown, some 
types of leukemia derive from typical mutations that accumulate in 
hematopoietic stem cells HSCs, a subpopulation of cancer cells within the 
tumor with common phenotypic properties. However, it is unclear whether 
there is a predisposing event to the acquisition of known mutations in leukemia. 
Leukemia are blood cancers, and the hematopoietic system is one of the best 
tissues to study the notion of the cancer or LSCs. Since the 1970s, the concept 
of tumorigenic LSCs has emerged and the small subset of leukemic cells was 
well characterized as capable of extensive proliferation in vitro and in vivo. 
In hematopoietic system, HSCs can be divided into a long-term subset (LT-
HSC), capable of undefined self-renewal, and a short-term subset (ST-HSC) 
that self-renew for a well-defined interval. HSCs give rise to non-self-renewing 
oligolineage progenitors, which in turn lead to a progeny with a more restricted 
differentiation potential, and finally to mature cells. 
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Since normal stem cells and LSCs share the ability to self-renew, as well as 
various developmental pathways, it is possible that LSCs derived from HSCs 
that have accumulated mutations.  
In CML it is well known the pathogenesis hallmark and the life expectancy of 
patients has improved significantly with target therapy, but remains unclear 
why many of them resistant or relapse after stopping treatment. Therefore, 
many studies have focused their attention on LSC. 
The BCR-ABL1 fusion protein can be found in myeloid, erythroid, B lymphoid, 
and occasionally T lymphoid cells in the majority of CML patients, suggesting 
that the original translocation takes place in LT-HSCs. However, as the BCR-
ABL1 gene was detected in endothelial cells of CML patients [70], it has been 
suggested that the BCR-ABL1 fusion gene may be present in an earlier stage 
such as putative hemangioblast cells, a very primitive cell population with both 
hematopoietic and endothelial differentiation potential. Nevertheless it has yet 
to be clarified [71]. A very interesting study has shown that primitive non cycling 
BCR-ABL1 positive cells escape the cytotoxic effects of Imatinib suggesting 
that the mechanisms governing induction of cycling of CML stem cells are 
complex and at least in part, independent of BCR-ABL1 signaling [72, 73]. To 
confirm this, recent studies have shown that induced pluripotent stem cells 
(iPSCs) derived from CD34+ blood cells isolated from CML patients (CML-
iPSCs) resisted to TKI treatment, whereas hematopoietic progenitors obtained 
from iPSCs partially recovered TKI sensitivity, after induction of hematopoietic 
differentiation. Thus, their survival did not depend on BCR-ABL11 [74].  
Tumor cell population with stem cell-like properties often express pluripotency 
related gene such as Nanog, octamer-binding transcription factor 4/3 (Oct4/3) 
and sex-determining region Y HMG-box 2 (Sox2) which are essential 
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transcription factors in embryonic stem cells (ESCs). These transcription 
factors are involved in various somatic cancers and drive tumor development 
[75]. Indeed, a particular feature of CSCs has been described in Lucena cell 
line resistant to chemotherapy (MDR) derived from the parental Ph+ cell line 
K562. These cells expressed the phenotypic profile CD34+ CD38- that is the 
hallmark of the early stage hematopoietic stem cells [76]. Furthermore, high 
levels of stem cell markers Sox2, Oct4 and Nanog have been observed in 
another MDR cell line selected with doxorubicin compared to the parental 
K562 cells [77]. These data indicate that the stem cell markers contribute to 
the high malignant potential of LSCs and may be responsible for drug 
resistance in CML patients too. 
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1.6 Homeobox protein Nanog  
The Nanog gene is a member of the homeobox family of DNA binding 
transcription factors.  
The name Nanog derives from Tır nan Og, the mythical Celtic land of youth 
and was first time identified in 2003 in a screen for pluripotency promoting 
genes in mouse ES cells [78, 79]. Nanog is known as a master transcription 
factor essential for maintaining cell stemness but the precise mechanism 
involved in the regulation of stem cell self-renewal and pluripotency are still 
poorly understood. Many studies have shown that Nanog with Oct4 and Sox2 
is involved in the maintenance of pluripotency and self-renewal in 
undifferentiated ES cells [80]. Interestingly, recent evidence has revealed that 
Nanog is also one of key transcription factors that could reprogram a human 
somatic fibroblast into an embryonic stem cell-like pluripotent cell, termed 
inducible pluripotent stem cell (iPS) [81].  
The human Nanog gene is located on chromosome 12 at 12p13.31 spans 
approximately 7 kb and consists of four exons [82]. In this region, Nanog gene 
can undergo tandem duplication, which generates two copies (97% identical), 
but their transcripts are often differentially spliced.  
The second copy, known as Nanogp1 or Nanog2, is a pseudogene and has 
regions with high homology to Nanog introns and exons. To date are known 
11 Nanog pseudogenes (NanogP2-NanogP11) located on different 
chromosome. They are the results of mRNA retrotransposition characterized 
by the absence of introns 5’ promoters sequences [83]. Nanog is a 305 amino 
acids protein with three functional domains: the N-terminal domain, which 
contains 94 amino acids (amino acid 1-95); the homeobox domain (amino acid 
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96–155), which contains 60 amino acids; the C-terminal domain with 151 
amino acids (amino acid 156–305). The N-terminal is rich in serine, threonine, 
and proline, providing a structural motif for the transcriptional activity of 
Nanog1. This region is tightly regulated through phosphorylation or other post-
translational modifications. The C-terminal region contains two potent 
transactivation subdomains [84, 85]. The homeobox domain, in the central 
region, contains a DNA-binding motif; its N- and C-terminal regions are shown 
to contain nuclear localization sequences and its middle region is reported to 
harbor potent nuclear export motif, allowing the Nanog1 protein to transport in 
and out of the nucleus [86]. Nanog1 and Nanog2 are expressed in pluripotent 
stem cells and have a length of 232 amino acids, then pseudogene NanogP7 
and P8 
The isoform P2, P4, P5, P9 and P10 of Nanog protein are truncated proteins 
due to premature stop codon, while Nanogp7 and P8 do not contain stop 
codons and are able to encode full-length proteins. In particular, NanogP8 
encodes a 305 amino acids protein that differs from the Nanog1 gene by only 
three amino acids. Since Nanog is also found in derivative ES cells and in the 
developing germ line of mammals, it is essential for early embryonic 
development [87]. Nanog has been shown to maintain the pluripotency of ES 
cells even in the absence of the LIF/Stat3 pathway. 
Leukemia inhibitory factor (LIF) is a member of the IL-6 cytokine family and it 
is responsible for maintaining the cells self-renewal in ES. 
The presence of LIF leads to the activation of the JAK and Stat signaling, in 
particular Stat3 activation is sufficient to prevent ES cells differentiation in the 
presence of serum [88]. In the absence of LIF, Oct3/4 is unable to prevent the 
ES cells differentiation into the trophoectoderm lineage and elevating Oct3/4 
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levels does not rescue pluripotent ES cells from reverting back to a 
differentiated state.  
Nanog overexpression is sufficient: 1) to drive cytokine-independent self-
renewal of undifferentiated ES cells; 2) to avoid the need for LIF/Stat3 
expression to block ES cells differentiation into the primitive endoderm; 3) to 
support ESC self-renewal. These evidences suggest that Nanog acts 
orchestrating the molecular switch to a purely undifferentiated state [87]. 
Although the mechanisms through which Nanog regulates stem cell 
pluripotency are still unclear, it has been proposed that Nanog regulates 
pluripotency mainly with two mechanisms. It acts as a transcription repressor 
for downstream genes that are important for cell differentiation, such as Gata4 
and Gata6. On the other hand, it promotes the activation of positive self-
renewal genes, such as Rex1 and Oct4. Recent study has been reported that 
Nanog may be regulated by Stat3 and interacts with Wnt and BMP4 signaling 
pathways, too malignancy [88]. Suzuki A and colleagues demonstrated that 
phosphorylated Stat3 can bind the promoter region of Nanog and activates its 
transcription. On the other hand, Bourguignon reported that Nanog forms a 
complex with Stat3 in the nucleus leading to Stat3 specific transcriptional 
activation and multidrug transporter, MDR1 (P-glycoprotein) gene expression, 
which are associated with cell proliferation [89]. Several findings suggest that 
Stat3-Nanog interaction plays an important role in cancer. 
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1.6.1 The role of Nanog in malignant phenotype of cancer stem cells 
Functional studies suggested the role of Nanog in malignant disease, 
with implications in cancer prognosis and anticancer therapeutics. Therefore, 
its expression correlates with several oncogenic signal transduction pathways 
involved in cell proliferation, clonogenic growth, tumorigenicity, invasiveness, 
and therapeutic resistance. CSCs and ESCs are characterized by a very 
similar proprieties, such as fast proliferation and poor differentiation state. As 
well as in ESC also in CSCs, Nanog appears to function as a vital transcription 
factor of cell cycle progression through the positively regulation of CDK6 and 
CDC25A genes [90]. On the other hand, Nanog negatively regulates Bcl-2 
expression, suggesting that it could be involved in drug resistance of CSCs by 
blocking the induction of apoptosis [91]. Generally, Nanog mRna is not 
observed in the stem cells of adult organism, but is heterogeneously 
expressed in both the nucleus and cytoplasm of several type of human cancer: 
such as embryonic carcinoma breast cancer, glioma, retinoblastoma, colon-
rectal and ovarian cancer, prostate cancer and hepatocellular carcinoma [92]. 
These observations suggest the functional role of Nanog in tumor 
development, disease progression and Epithelial Mesenchymal Transition 
(EMT) [86]. 
Furthermore, many studies have shown that Nanog overexpression correlates 
with a poor prognosis of patients with several malignancies. The Nanog 
expression promotes tumor cell growth, anti-apoptosis proprieties and 
metastasis in Nasopharyngeal Carcinoma (NPC) as well as in Human 
Hepatocellular Carcinoma (HCC) cancer cells. Due to the Nanog expression, 
HCC cells exhibit a high capacity to metastasize showing a chemotherapy 
resistance to sorafenib and cisplatin too [93]. Ovarian cancer is the most lethal 
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in all gynecological malignancies and high levels of Nanog mRNA and Nanog 
protein were observed in ovarian cancer cells. They expressed resistance 
properties such as sphere-forming and tumor regeneration ability and 
chemotherapy resistance [94]. It has been shown that the expression of Nanog 
correlates with drug resistance to cisplatin in oral squamous carcinoma 
(OSCC) cells [88]. Oct4 and Nanog expression may be a key factor in the 
resistance to chemotherapy and tumor growth of breast CSCs. Thus, down 
regulation of Oct4 or Nanog expression may reduce chemotherapeutic drug 
resistance and tumorigenicity in breast CSCs [95]. Furthermore, it was also 
observed that the Nanog and Oct4 expression was significantly correlated with 
larger tumor sizes and vascular invasion, likewise the median recurrence-free 
survival (RFS) was significantly shorter than that of patients with Nanog-
negative tumors. Furthermore, Nanog expression levels correlate with stage 
and prognosis of cervical cancer in patients, suggesting that Nanog may 
support the development and progression of cervical cancer. It facilitates 
immune evasion capabilities among CSCs through T cell leukemia/lymphoma 
1A/Akt (Tcl1a/Akt): a signaling axis potentially conserved in some of other 
cancer types [96].  
A correlation with poor prognosis was also described for Nanog in leukemia 
field: in mixed lymphocytic leukemia (MLL) Nanog2 is involved in regulating 
leukemic stem cell functions [97]. Instead, in acute T cell lymphoblastic 
leukemia (T-ALL) NanogP8 is associated with gain of proliferation, increased 
self-renewal, and reduced apoptosis via blocking cell cycle progression 
through p53 [98]. These findings demonstrated that Nanog is a pro-
tumorigenic factor that may assist in the clinic as a biomarker for cancer 
diagnosis, prognosis and predictor of anticancer therapeutic efficacy.  
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In the past, our group has carried out microarray experiments on gene groups 
selected through the bioinformatics algorithm of “Di Bernardo” team. The gene 
expression of Nanog was significantly increased in a Ph+ cell lines resistant to 
Imatinib. These results have a particular interest in context of TKI resistance 
because it was observed that the expressions of Oct4, Sox2, and Nanog, were 
elevated in a Ph+ doxorubicin resistant cell lines compared to parental cell 
lines. This resistant cell line exhibited more potent in vitro and in vivo tumor-
initiating properties, as revealed by sphere assay, self-renewal assay, soft 
agar assay, and animal studies [77]. Thanks to consolidate experience of our 
research group in the study of resistance mechanism of CML, it will be 
interesting to assess whether Nanog has a role in the TKI resistance observed 
in patients with CML-CP.  
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Figure 6. Graphical illustration of the NANOG gene sequence (A) and 
structure of Nanog protein (B). NANOG mRNA variants NANOG-001 and -002 
encode for a protein with a length of 305 amino acid (aa) and 289 aa, respectively. 
NANOG-001, the 305 aa long protein with a molecular weight of 34.6 kDa is usually 
analyzed to study the role of NANOG (B). It consists of a Serine-, Threonine- and 
Proline-rich N-terminal region as well as eight W-repeats at its C-terminus (aa 104-
151). The DNA-binding facilitating homeodomain spans from aa 95-155. Formation of 
secondary structures (helix, strand and turn) occurs mainly within the homeobox-
coding region.[99]  
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2. AIMS 
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2. Aims of work 
 
The introduction of BCR-ABL1 tyrosine kinase inhibitors has revolutionized the 
therapy of CML patients; indeed, nowadays, patients diagnosed with CML and 
treated with TKIs are expected to have a substantially longer survival.  
However, despite the success of target therapy, the majority of CML patients 
develop resistance to TKI therapy and, in particular, to first generation TKI 
Imatinib, which still represents the first-line therapy of CML. 
If on one hand, BCR-ABL1 dependent Imatinib resistance can be overcome 
by second or third generation TKIs, on the other hand, the molecular 
mechanisms that underlie BCR-ABL1 independent Imatinib resistance are not 
well characterized. 
Different studies have demonstrated the role of Nanog in promoting 
tumorigenesis and chemoresistance through the regulation of cancer stem 
cells in solid tumors; indeed, elevated Nanog levels correlate with a poor 
disease-free and overall survival in patients with breast, prostatic, ovarian, 
gastric, lung or hepatocellular carcinoma. 
Nanog is transcriptional factor and a stem cell marker required for maintaining 
pluripotency of embryonic stem cells and preventing cell differentiation. These 
findings highlight that it is certainly interesting to investigate also the potential 
role of Nanog in controlling leukemic stem cells (LSC) population, in drug 
resistance and poor prognosis of CML patients.  
The aim of this work is to evaluate the involvement of Nanog in the BCR-ABL1 
independent TKI resistance of leukemic cell line. Finally, we will corroborate 
our in vitro results on CML patients in order to understand whether Nanog may 
45 
 
be considered as an early marker of molecular response in CML-patients 
treated with first and second generation TKIs. 
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3. RESULTS 
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3.1 Nanog protein expression is modulate in K625 cell line 
after Imatinib exposure. 
To determinate whether pluripotent stem cell marker Nanog may have 
a potential role on resistance to TKI treatment on BCR-ABL1 positive cell lines, 
we first examined the expression of Nanog in Ph+ K562 cells, derived from a 
patient affected by CML-BP. 
In particular, we treated K562 cell line with a clinical relevant concentration of 
Imatinib (5uM Ima), and analyzed the expression level of Nanog after 72hrs. 
Densitometric quantification showed that the band at 42 kDa of Nanog was 
significantly more intense in K562 treated with 5uM Ima than in untreated K562 
(i.e. K562 cell line cultured in the presence of regular media – RM – and mock 
drug vehicle represented by PBS). 
Data were shown in a single exemplificative experiment (Fig. 7, Panel A), or 
as average of the ratio observed between Nanog and β-Actin housekeeping 
protein levels in three independent experiments (Fig. 7, Panel B).  
In order to understand whether Nanog modulation was related to the time of 
Imatinib exposure, we performed a time course experiment in which K562 cells 
were treated with 5uM Ima for 24, 48 or 72 total hours. Nanog protein 
expression is significantly increased (p=0.05) already after 24 hours of 
treatment (Fig. 8), but also during the considered time course (72hrs).  
Data were shown in a single exemplificative time course experiment (Fig. 8 – 
Panel A), or as average of the ratio observed between Nanog and β-Actin 
housekeeping protein levels in three independent experiments (Fig. 8– Panel 
B). 
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Figure 7. Western blotting analysis of Nanog protein expression in K562 
cell line treated with 5uM Imatinib, compared to β-Actin housekeeping 
protein. Nanog protein expression is shown in a single exemplificative 
experiment (Panel A), or as average of the ratio observed between Nanog 
and β-Actin housekeeping protein levels in three independent experiments 
(Panel B). 
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Figure 8. Western blotting analysis of Nanog protein expression in K562 cell 
line treated for 24, 48 and 72 hours with 5uM Imatinib, compared to β-Actin 
housekeeping protein. Nanog protein expression is shown in a single 
exemplificative experiment (Panel A), or as average of the ratio observed 
between Nanog and β-Actin housekeeping protein levels in three independent 
experiments (Panel B).  
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3.2 Nanog protein expression increased in a dose dependent 
manner after Imatinib treatment 
To evaluate whether Nanog expression is modulated by Imatinib in a 
dose related manner, we exposed K562 cells to different Imatinib 
concentrations (0.5 uM, 1uM, 2uM and 5uM Ima) for 24h. Although Nanog 
protein is detectable at low level by Western blotting (WB) in untreated K562 
cells (Cnt), densitometric band quantification showed a significant up-
regulation of the protein expression even by the lowest Ima concentration of 
1uM after 24h of treatment.  
Increasing the Imatinib concentration to 5 uM, we observed a significant up-
regulation of Nanog protein (p=0.022). Data were shown in a single 
exemplificative experiment (Fig. 9, Panel A), or as average of the ratio 
observed between Nanog and β-Actin housekeeping protein levels in three 
independent experiments (Fig.9 – Panel B). 
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Figure 9. Western blotting analysis of Nanog protein expression in K562 
cell line treated for 24 hours with a dose escalation of 0.5 uM, 1uM, 2uM 
and 5uM Imatinib, compared to β-Actin housekeeping protein. K562 cells 
treated with 1-5uM Ima dose escalation show a significant dose 
dependent increase of Nanog protein expression at 24h. Nanog protein 
expression is shown in a single exemplificative experiment (Panel A), or 
as average of the ratio observed between Nanog and β-Actin 
housekeeping protein levels in three independent experiments (Panel B). 
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3.3 Second generation TKI induce increasing expression of 
Nanog protein. 
In order to prove that the modulation of Nanog by TKI treatment were 
independent from first generation TKI, we treated K562 cells with second 
generation TKI Nilotinib (Nilo), that is not sharing with Imatinib any off target 
protein signaling down-regulation. In particular, we treated K562 Ph+ cell line 
with 50nM, 100nM of Nilotinib.  
The data of WB densitometric band quantification showed that Nanog protein 
levels increase in K562 cell line when treated with either 50nM or 100nM of 
Nilotinib, but only after 72 hours (p value < 0.05). Data were presented in a 
single exemplificative experiment (Fig. 10 – Panel A), or as average of the 
ratio observed between Nanog and β-Actin housekeeping protein levels in 
three independent experiments (Fig.10 – Panel B). 
These finding supports the idea that Nanog expression may related to BCR-
ABL1 inhibition in CML Ph+ cell line when exposed to first and second 
generation TKI used in clinical practice. 
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Figure 10. Western blotting analysis of Nanog protein expression in K562 
cell line treated for 72 hours with a dose escalation of 50nM or 100nM 
Nilotinib, compared to β-Actin housekeeping protein. K562 cells treated for 
72h with 50nM and 100nM Nilo show a significant dose dependent 
increase of Nanog protein expression. Nanog protein expression is shown 
in a single exemplificative experiment (Panel A), or as average of the ratio 
observed between Nanog and β-Actin housekeeping protein levels in three 
independent experiments (Panel B). 
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3.4 Nanog expression is modulated at a transcriptional level in 
K562 cell line after exposure to first and second generation 
TKIs.  
 
In our study, we attempted to evaluate whether exist any correlation 
between Nanog expression at protein or mRNA level after TKIs treatment in 
Ph+ K562 cell line. 
Thus, RT-qPCR for Nanog mRNA expression was carried-out on K562 cell line 
treated with increasing doses of Imatinib (0.1uM, 0.5uM, 1uM, 2uM and 5uM) 
or Nilotinib (5nM, 10nM, 50nM, 100nM and 500nM).  Total mRNA was isolated 
from K562 cell line at 24, 48 and 72 hours after TKI treatment. 
As shown in Figure 11, Nanog mRNA expression was significantly increased 
in K562 cell line treated with Imatinib during the time course of 72 hours. 
Moreover, we confirmed that Nanog expression is also modulated in a dose 
dependent manner at the transcriptional level. 
Furthermore, the evaluation of Nanog mRNA in K562 cells treated with 
Nilotinib, show to be a more sensitive test than WB, since able to highlight a 
significant modulation of the transcript during the time course and also at the 
very low concentration of 10nM of Nilotinib (Fig. 12). 
Moreover, we demonstrated that Nanog mRNA expression is inversely 
correlated to BCR-ABL1 mRNA expression. Indeed, RT-qPCR was conducted 
to analyze p210 mRNA expression in K562 cell line after 5uM Ima exposure.  
As we expected, p210 mRNA levels were significantly reduced after Ima 
treatment, while Nanog mRNA expression significantly increased (Fig.13). 
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Figure 11. Gene expression analysis by RT-qPCR of Nanog mRNA 
expression in K562 cells treated with 0.1uM, 0.5uM, 1uM, 2uM or 5uM Imatinib 
dose escalation for 24, 48 and 72 hours, normalized by ABL control gene. 
Nanog mRNA expression shows a dose dependent increase in K562 cells 
treated with increasing doses of Ima; the increase is particularly significant at 
72 h.  
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Figure 12. Gene expression analysis by RT-qPCR of Nanog mRNA 
expression in K562 cells treated with 5nM, 10nM, 50nM, 100nM or 500nM 
Nilotinib dose escalation for 24, 48 and 72 hours, normalized by ABL control 
gene. Nanog mRNA expression shows a dose dependent increase in K562 
cells treated with increasing doses of Nilo; the increase is particularly 
significant at 72 h. 
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Figure 13. Gene expression analysis by RT-qPCR of Nanog mRNA and p210 
mRNA expression in K562 cells treated with 5uM Imatinib, normalized by ABL 
control gene. p210 mRNA levels (blue) were significantly reduced in K562 
treated with Ima, compared to control; instead, Nanog mRNA expression (red) 
is significantly increased in K562 treated with Ima, compared to control. 
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3.5 K562 cells survived after TKI exposure express high levels 
of Nanog protein. 
It has been reported that Ph+ staminal cells are not sensible to TKI-
induced apoptosis.  
In particular several studies have shown that the iPS Ph+ cells are refractory 
to the pharmacological action of TKIs, as a result their survival did not depend 
on BCR-ABL1. 
Thus, we sought to evaluate the correlation between Nanog overexpression 
and cellular viability after TKI treatment. In particular, we exposed K562 cell 
line to 5uM Ima for 72 hours. We selected vital K562 cells through the 
elimination of no vital cells by Dead Cell Removal Kit (Miltenyi) and we 
confirmed cell viability by Trypan blu exclusion. 
After the exclusion of the dead cells, we evaluated Nanog protein expression 
in the selected viable K562 cells survived after Imatinib treatment with 
densitometric band quantification analysis, showing that the Nanog 
overexpression is present in this cell fraction (Fig. 14 A, C). 
Moreover, we sought to evaluate whether this overexpression could persist 
overtime. Thus, the selected alive Ima-treated K562 cells were re-plated in a 
fresh medium without Imatinib for 72 hours. WB analysis show a significant 
persistence of up-regulation of Nanog protein expression (Fig.14 B, C). 
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Figure 14. Western blotting analysis of Nanog protein expression in K562 cells 
subjected to viability selection after 72 hours of 5uM Imatinib treatment, 
compared to β-Actin housekeeping protein. Nanog protein expression analysis 
in alive K562 cells after 72h of Ima treatment withdrawal.  
A,C) Nanog protein expression in viable selected K562 cells survived after 72h 
of Ima treatment, compared to untreated control; B,C) Nanog protein 
expression in viable selected K562 cells survived after 72h of Ima treatment, 
and re-plated in the absence of Imatinib.  
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3.6 Transcription levels of Nanog mRNA are up-regulated with 
warning/failure response in CML patients treated with Imatinib 
as front line therapy. 
In order to evaluate whether Nanog expression could have a role in the 
regulation of CML patients response to TKIs therapy, we performed a RT-
qPCR for the expression of Nanog mRNA in 60 CML patients at diagnosis 
enrolled in Hematological Clinical Unit of Federico II University.  
First, we distributed the enrolled CML patients based on drug treatment; in 
particular 25 patients received Imatinib as front-line therapy, while 35 received 
Nilotinib as front-line therapy. Thereafter, we stratify CML patients in three 
distinct response categories based on the molecular  BCR/ABL1 analysis 
performed at 12 months from the beginning of Imatinib and Nilotinib therapy: 
patients achieved optimal response (OR), patients with a warning response 
(WR) and patients with a failure response (FR) (Baccarani M et al, Ann 
Hematol 2016). 
The Nanog expression was evaluated in cells of BM and peripheral blood (PB) 
samples of the enrolled CML patients at diagnosis. 
We observed a significant correlation between patients outcome and the 
expression of Nanog in pre-treatment patient’s samples. The Nanog gene 
expression was normalized by the expression of ABL1 mRNA (normalized 
copy number, NCN). 
In PB samples at diagnosis of WR/FR patients treated with Imatinib, the 
normalized copy number of Nanog was 25.65 ± 18, whereas patients with OR 
showed 1.12 ± 0.36 (Fig. 14). Moreover, as shown in Figure 14 transcription 
levels of Nanog mRNA were also significantly increased in BM samples of 
patients treated with Imatinib. 
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The same analysis was conducted in a cohort of 35 CML patients at diagnosis 
treated with Nilotinib as first line therapy. Both the PB samples that BM sample 
of WR/FR patients showed a significantly higher expression of Nanog mRNA 
(NCN 3.941± 1.951 vs 0.13 ± 0.048, p<0.05).n 
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Figure 15. Gene expression analysis by RT-qPCR of Nanog mRNA 
expression in cells from bone marrow (BM) and peripheral blood (PB) samples 
of 25 CML patients at diagnosis treated with Imatinib normalized to Abl control 
gene. Nanog mRNA expression is higher in warning/failure responders than in 
optimal responders both in PB (pvalue 0.05) and in BM (pvalue 0.03). 
 
 
.  
* pvalue < 0,05 
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Figure 16. Gene expression analysis by RT-qPCR of Nanog mRNA 
expression in cells from bone marrow (BM) and peripheral blood (PB) samples 
of 35 CML patients treated with Nilotinib, normalized to Abl control gene. 
Nanog mRNA expression is higher in warning/failure responders than in 
optimal responders both in PB (pvalue 0.05) and in BM (pvalue 0.03). 
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4. DISCUSSION 
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4.1 Conclusion e future prospective. 
The emergence of drug resistance continues to limit the success in finding a 
cure for hematologic malignancies. CML represents a disease that is initially 
driven by the well-established oncogenic event resulting in the expression of 
the BCR-ABL1 fusion oncogene. The onset of drug resistance in CML patients 
during tyrosine kinase inhibitors therapy leads to a failure in complete 
eradication of CML disease and, consequently, to the persistence of minimal 
residual disease, responsible of disease relapse.  
To date, the most clear and common mechanisms of drug resistance, in 
particular to first generation TKI Imatinib, are those due to the acquisition of 
point mutations within the kinase domain of BCR-ABL1; these mutations have 
become druggable targets since the introduction of second and third 
generation TKIs. Otherwise, the molecular pathways activated in cases of 
resistance phenomena not dependent from BCR-ABL1 mutations are still not 
clearly described. 
In this work, we evaluated the contribution of the transcription factor Nanog in 
BCR-ABL1 independent TKI resistance mechanisms.  
Nanog is known as a transcription factor required for maintaining the 
pluripotency of embryonic stem cells, but several correlation studies have 
demonstrated that also CSCs express high levels of Nanog. Indeed, Nanog is 
overexpressed in malignant, high grade, poorly differentiated cancer cells. In 
particular, Nanog overexpression is found in many solid tumors, such as 
breast, ovarian, colorectal, gastric, lung, hepatocellular and prostate 
carcinoma as well as in head and neck squamous cell carcinoma. Moreover, 
Nanog expression is been detected not only in solid tumors, but also in a blood 
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tumor, the acute lymphoblastic leukemia (ALL), that is a disease associated 
with a very poor outcome [92]. Several studies have highlight an increased 
expression of stem pluripotent cells markers such as Oct4, Sox2 and Nanog, 
in Ph+ cell line that shown a drug resistance.[77] 
Consequently, in this work we investigated the possible role of Nanog in TKIs 
resistance in CML. 
Our results have demonstrated that Nanog protein and mRNA are expressed 
at very low level in K562 Ph+ cell line, but their up-regulation is observed in 
Ph+ cell line treated with increasing doses of Imatinib. This data underline for 
the first time that Nanog protein is up-regulated after inhibition of the oncogenic 
pathway of BCR-ABL1 in CML cells.  
In addition, to corroborate our data, we also proved that the up-regulation of 
Nanog is not related to Imatinib treatment, but also to the BCR-ABL1 inhibition 
obtained through the treatment with a second TKI generation represented by 
Nilotinib.  
Furthermore, we investigated whether Nanog mRNA correlates with the 
expression at the protein level. Thus, we optimized a RT-qPCR as a validated 
and standardized molecular test to evaluate Nanog expression in either cell 
line or primary human cells derived from BM or PB samples of patients with 
leukemia. 
The expression of Nanog mRNA in CML cell line increases overtime after 
Imatinib or Nilotinib treatment, in a dose-dependent fashion, corroborating our 
results obtained at the protein level.   
Moreover, in order to investigate a possible correlation between Nanog 
expression and BCR-ABL1 oncogene, we conducted a gene expression 
analysis on CML cell line treated with Imatinib to evaluate both BCR-ABL1 and 
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Nanog transcript levels. The analysis has highlighted that Nanog expression 
inversely correlates with BCR-ABL1 expression. Indeed, after Imatinib 
treatment, BCR-ABL1 expression was reduced, while Nanog expression was 
significantly increased. 
We could not exclude that Nanog could be a marker of apoptotic or dying cells 
in our experimental setting. Thus, we selected all the viable cells survived after 
Imatinib treatment showing that Nanog overexpression was a prerogative of 
this subpopulation. Moreover, keeping the cells in culture for an additional 
72hrs in the absence of TKI, we also proved that the selected cells were real 
survived cells, capable of proliferation, and in which Nanog was still up-
regulated respect to the control. Finally, we evaluated Nanog expression levels 
in a cohort of CML patients treated with first and second generation TKI. The 
patients have been enrolled in the Division of Hematology at University of 
Naples Federico II and was stratify in two experimental groups according to 
the treatment received. Nanog expression evaluated in hematopoietic cells in 
patients with warning or failure response to Imatinib therapy resulted up-
regulated respect to that observed in optimal responder patients. The same 
analysis was carried out in the second group of 34 patients receiving Nilotinib. 
The Nanog expression was significantly unregulated both in peripheral blood 
and bone marrow samples warning/failure responders.  
All these data strongly suggest that Nanog could have a role in Ph+ cells 
resistant to first or second generation TKI treatment. Its expression could be 
evaluated not only as a drug resistance marker in CML disease, but also as a 
prognostic and predictive biomarker at diagnosis for unfavorable patient 
outcome. 
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Our future perspectives are basically aimed to the development of in vitro 
functional studies in order to clarify Nanog function in CML disease, through 
gene expression assays that could allow us to determine the intracellular 
pathogenic pathways that regulate Nanog upstream and downstream signal 
transduction. 
Recently, Songna Yin at al described that Nanog expression was down 
regulated by the action of phosphatase SHP1 in blastocyst cells. In particular, 
SHP-1 regulates the expression of Nanog by dephosphorylation of STAT3 
[100].  
Since, our group previously shown that SHP-1 expression is lower in BM or 
PB samples of patients affected by CML resistance to Imatinib than in patients 
with Optimal response. 
In a future prospective, it will be interesting to assess whether Nanog has a 
role in the TKI resistance observed in patients with CML-CP and whether there 
is a relationship with modulation of SHP1. 
In addition, we intend to extend the number of CML patients enrolled in our 
study and to evaluate Nanog expression at different follow-up time points 
during TKI in order to evaluate the possible role of Nanog as early prognostic 
marker of patient response in CML disease. 
The emerging role of Nanog in CML will lead to a deeper understanding of 
molecular dynamics involving pathways related to TKI resistance. Moreover, 
Nanog could represent a novel and un-discovered druggable targets in order 
to reduce the emergence of TKI resistance. 
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5. Methods 
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5.1 Cell cultures 
 
5.1.1. K562 cell line 
K-562 human BCR-ABL1 positive cell line (DSMZ) were maintained in culture 
at a density of 0.5 x 106 cells/ml in RPMI 1640 medium (Aurogene) 
supplemented with 10% fetal bovine serum (FBS; Aurogene), 1% L-glutamine 
(L-Glu, Aurogene), and 1% penicillin/streptomycin (P/S, Lonza) at 37°C in 5% 
CO2 in a humidified incubator. Cell line viability was assessed by Trypan Blue 
exclusion using the Burker chamber. 
 
5.2 Viable cell isolation 
Dead Cell Removal Kit (Miltenyi) was used to separate dead cells from cell 
cultures. Briefly, K562 cells was collected and centrifuged at 1000 rpm for 10 
min; the supernatant was completely removed and cell pellet was resupended 
in 100 µL of Dead Cell Removal MicroBeads. After incubation of 15 minutes at 
room temperature, a positive selection column type MS has been chosen and 
placed in the magnetic field of a MACS® Separator. The column has prepared 
by rinsing with 1X Binding Buffer. The cell suspension was applied in 500 µL 
of 1X Binding Buffer into the column, so that the negative cells passed through. 
Live cell fraction  was collected  and rinsed with 1X Binding Buffer. 
 
5.3 Drug and Reagents 
Imatinib mesylate was supplied by Novartis Pharma. It was diluited in DMSO 
as a 10 mmol/L stock solution and stored in aliquots at −20°C.Nilotinib was 
supplied by Novartis Pharma. It was diluited in DMSO as a 10 mmol/L stock 
solution and stored in aliquots at −20°C. Dasatinib was  supplied by Bristol-
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Myers Squibb. It was diluited in DMSO as a 10 mmol/L stock solution and 
stored in aliquots at −20°C. 
 
5.4 Western blotting analysis 
To obtain total lysates for immunoblotting analysis, K562 cells were washed in 
PBS and collected by gentle scraping in ice-cold RIPA buffer supplemented 
with protease inhibitor cocktail II (Roche Diagnostic, Monza, Italy). After 
sonication and incubation for 1 hour on ice, we centrifuged at 12,000 rpm at 4 
°C for 30 minutes and collected the supernatants. 
The protein content of resulting supernatant was determined using the 
Bradford reagent. 30 μg of proteins were mixed with a Laemmli sample buffer; 
then, they are applied and resolved on SDS-PAGE 10% polyacrylamide gels. 
Following transfer onto PVDF membranes, non-specific binding sites were 
blocked by incubation for 2 hrs at 4°C with 5% non-fat dry milk (Bio-Rad 
Laboratories, Milan, Italy) in PBS-Tween buffer; subsequently, incubated with 
primary antibodies overnight at 4°C. After three 10-min washes with PBS-T, 
the membranes were incubated 1h with the appropriate secondary antibody. 
Excessive antibodies were then washed away three times (10 min) with PBS-
T. Immunoblots were visualized by enhanced chemiluminescence (ECL) 
Western Blotting Substrate (Thermo Scientific). Films were developed using a 
standard photographic procedure and the relative levels of immunoreactivity 
were determined by densitometry using ImageJ Software (NIH, Bethesda, MA, 
USA).Primary antibodies used were: rabbit polyclonal anti-Nanog (1:1000 Cell 
Signaling), mouse polyclonal β-actin (1:15.0000 Sigma Aldrich) Secondary 
antibodies were: goat anti rabbit (1:10000 Santa Cruz Biotechnology), goat 
anti mouse (1:10000 Santa Cruz Biotechnology). 
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5.5 Real-time quantitative Reverse Transcription - Polymerase Chain 
Reaction (RT-qPCR) 
K562 and CML patients cells total RNA was extracted using RNeasy Mini Kit 
(Qiagen), following the manufacturer’s instructions, and quantized using 
Nanodrop 8000 (Thermo Scientific). Nanog mRNA expression was evaluated 
by One-step RT-qPCR kit (Life Technologies gene expression assay), starting 
from 1 µg of RNA and following the manufacturer’s instructions; one-step RT-
PCR kit combines the first-strand cDNA synthesis (reverse transcription) 
reaction and PCR reaction in the same tube, simplifying reaction setup and 
reducing the possibility of contamination. The reverse transcription reaction 
consists of 15 min at 48°C; the activation of AmpliTaq Gold® DNA Polymerase 
of 10 min at 95°C. The qPCR was performed using ABI PRISM 7900HT 
Sequence Detection System (Applied Biosystems); amplifications were carried 
out by 35 cycles of the following parameters: denaturation step at 95°C for 15 
sec, annealing and extension steps at 60°C for 1 min. ABL was used as 
housekeeping control gene. 
 
5.6 Statistical Analysis 
All data are presented as mean ± 1 SD. The student’s t test was used to 
evaluate the statistical significance of Nanog expression levels after TKIs 
treatment compared to untreated control, with a p value <.05 indicating a 
significant difference.  
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